The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis

Ejemplares similares

• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  por: Yunwen Xu, et al.
  Publicado: (2025)
• Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
  por: Deep Dutta, et al.
  Publicado: (2025)
• Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
  por: Frederick Berro Rivera, et al.
  Publicado: (2024)
• Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
  por: Muhammad Aaqib Shamim, et al.
  Publicado: (2024)
• Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
  por: Fu‐Shun Yen, et al.
  Publicado: (2025)